FDA Seeks Clearer Rules For Use Of Osteoporosis Meds
A U.S. Food and Drug Administration advisory panel on Friday recommended that makers of certain osteoporosis drugs associated with jaw disorders and leg fractures should clarify on labels how long the...To view the full article, register now.
Already a subscriber? Click here to view full article